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Imaging with 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography 
(PET/CT) is used to determine sites of abnormal glucose metabolism to predict high tumor grade, 
metastasis, and poor patient survival. However, not all tumors with increased 18F-FDG uptake 
show aggressive tumor biology, as evident from the moderate correlation between metastasis 
and high FDG uptake. We hypothesized that metastasis is likely attributable to the complexity 
and heterogeneity of the cancer microenvironment. To identify the cancer microenvironment that 
induces the epithelial-mesenchymal transition (EMT) process, tumor areas of patients with HCC were 
analyzed by immunostaining. Our data demonstrated the induction of EMT process in HCC cells with 
low proliferation under hypoxic conditions. To validate our finding, among HCC cell lines, HepG2 cells 
with highly increased expression of HIF1α under hypoxia were employed in vitro and in vivo. Major 
changes in EMT-associated protein expression, such as the up-regulation of N-cadherin and snail/slug 
are associated with decreased proliferation-related protein (PCNA) caused by glucose deprivation under 
hypoxia. Indeed, PCNA knockdown-HepG2 cells under hypoxia showed the induction of more EMT 
process compare to the control. Thus, HCC cells with low proliferative potential under glucose-deprived 
and hypoxic conditions show high probability for induced EMT process and promote cell invasion. 
This study investigates reasons as to why an EMT process cannot fully be predicted. Our observations 
indicate that rather than analyzing a single factor, an integrated analysis of hypoxia with low glucose 
metabolism and low cell proliferation might be helpful to predict the potential impact on induction of 
EMT process and promotion of cell invasion.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide and is associated 
with various risk factors such as hepatitis virus infection, aflatoxin exposure, fatty liver, or alcohol abuse1,2. HCC 
is a clinical, metabolic, and heterogeneous tumor with various phenotypes1–6. Tumors include proliferating, slow 
dividing, quiescent or necrotic/apoptotic tumor cell populations, as well as fast- or slow-migrating tumor cells7,8. 
Genetic heterogeneity in solitary disseminated tumor cells and metastasis has been shown by genetic and expres-
sion profiling studies9–15. One of the known causes of heterogeneity related to rapid cellular proliferation is the 
formation of abnormal vascular networks characterized by leaking and compressed blood and lymphatic vessels, 
creating hypoxic areas in the tumors. Tumor hypoxia induces metabolic reprogramming from mitochondrial oxi-
dation to glycolysis and drug resistance by activating pathways controlled by hypoxia-inducible factor (HIF)16,17. 
Moreover, there is a close relationship between hypoxia and tumor metastasis that leads to poor prognosis18–20.
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Epithelial-mesenchymal transition (EMT) is a complex trans-differentiation process that increases the migra-
tory and invasive ability of tumor cells and is an early step in cancer metastasis21,22. EMT process is associated 
with the proliferation capacity of cancer cells. It is known that mesenchymal-like tumor cells gain movement 
ability at the expense of proliferative potential by cell cycle arrest23–25. It involves complex cell reprogramming that 
renders the cells resistant to anti-cancer drugs for primary tumors and promotes cancer stemness properties26,27. 
Members of the classical cadherin family, such as N-cadherin and Vimentin, have been proposed as inducers of 
the EMT process28. The repression of E-cadherin during EMT is mediated by the binding of EMT transcription 
factors, including Snail and Slug26. The heterogeneity of the EMT spectrum has an impact on metastasis, resulting 
in some cells of the primary tumor colonizing the secondary site29,30. It remains controversial whether tumor cells 
innately have the ability to metastasize, or whether the metastatic ability is gained from a set of genetic and/or 
other changes that occur throughout tumor progression or from the tumor microenvironment.
Positron emission tomography/computed tomography (PET/CT) imaging for F-18 fluorodeoxyglucose 
(18F-FDG), a surrogate marker for measuring enhanced glycolysis, has been useful in capturing hypoxia-related 
metabolic reprogramming in patients with HCC. So far, HCC with increased FDG uptake on PET/CT imaging 
is associated with a higher frequency of metastasis31,32. However, as observed in a previous study, more than 50% 
of HCC patients with increased FDG uptake do not display tumor metastasis33. We hypothesized in this study 
that the remaining HCC patients with high FDG uptake may fail to promote metastasis because of the insufficient 
tumor microenvironment to induce the EMT process. The current study, therefore, aimed to further investigate 
the synergistic effects of glucose availability, hypoxia, and cellular proliferation on EMT in vitro using HCC cell 
lines and in vivo using xenografts and human HCCs.
Results
Hypoxia, GLUT1, Ki67, and EMT in human HCC specimen according to FDG uptake upon PET/CT. 
As described in the Methods section, patients with HCC were divided into two groups depending on glucose 
uptake – 10 patients with HCC showed high 18F-FDG uptake (TLR > 1.62) and 13 showed low 18F-FDG uptake 
(TLR≤1.62) on PET/CT imaging. Expression of HIF1α, GLUT1, and CD31 was investigated in these two groups. 
Tumor region of HCC tissue from HCC patients with high FDG uptake showed statistically significantly more 
positive regions of Hif1α expression and membranous GLUT1 as compared with HCC with low FDG uptake 
by immunostaining (Fig. 1A, Supplementary Fig. S2A,B). In HCC patients with high FDG uptake, there was no 
change in CD31 expression, but rather an uneven distribution of blood vessels in the tumor region (Fig. 1A and 
Supplementary Fig. S2C). In contrast, HCCs with low 18F-FDG uptake showed decreased expression of HIF1α 
and GLUT1, and well-organized, uniformly branched blood vessels, as confirmed by CD31 staining (Fig. 1B 
and Supplementary Fig. S2C). Next, qRT-PCR was carried out to determine the expression of the EMT-related 
genes, HIF1α and proliferating cell nuclear antigen (PCNA), as proliferation markers. Based on the qRT-PCR 
result, we observed statically no correlation between HIF1α and SNAl1 (R2 score = 0.04), HIF1α and CDH2 
(R2 score = 0.21), PCNA and SNAl1 (R2 score = 0.1), and PCNA and CDH2 (R2 score = 0.023) (Supplementary 
Fig. S4A). In addition, a TCGA analysis was performed for 360 human HCC samples (Supporting Fig. 4B). 
Spearman’s correlation analysis showed a significant positive correlation between EMT-related genes and the 
HIf1α gene. Interestingly, there is a significant, but weak negative correlation between the expression levels of 
SNAIL1 and PCNA mRNAs (Spearman r =−0.1885, P = 0.0003). To confirm mRNA expression data, GLUT1, 
Ki67, and EMT- related proteins were immunostained in hypoxia positive regions of human HCC. Most of the 
hypoxic areas showed expression of GLUT1, but not Ki67. Moreover, there were negative correlations between 
Ki67 expression and that of the EMT-related proteins, N-cadherin or vimentin (Fig. 1C and Supplementary 
Fig. S2D). Altogether, our data demonstrate that EMT-related proteins, such as N-cadherin or vimentin are dif-
ferentially expressed in HCC cancer cells depending on the proliferative rate under hypoxic conditions.
Sensitivity of different HCC cell types to hypoxic conditions. Our previous study showed that dif-
ferent types of HCC cells have different characteristics, including the uptake of glucose34. To confirm the results 
obtained from patients with HCC, we decided to select the HCC model system that mimics the heterozygous 
hypoxic conditions of patients with HCC. We examined HIF1α expression under hypoxic and normoxic condi-
tions in three HCC cell lines (HepG2, Hep3B, and Huh7). HepG2 and Hep3B cells showed increased expression 
of HIF1α after 8 and 24 h of exposure to hypoxic conditions (Fig. 2A). However, Huh7 cells, which have a high 
expression of HIF1a under normoxia, showed a mild increase in the expression of HIF1a under hypoxic con-
ditions. HepG2 and Hep3B xenograft models showed varying expression levels of GLUT1 and Ki67 depending 
on heterogeneous CAIX expression, a hypoxia-inducible metal-enzyme that promotes cancer cell survival and 
invasion via HIF1α activation (Supplementary Fig. S3). Therefore, HepG2 and Hep3B cells were selected to inves-
tigate the biologic effects of hypoxic conditions in HCC for further in vitro studies. In contrast, the Huh7 model 
has a high homogenous expression of CAIX, GLUT1, and Ki67 in most tumor regions.
Dysregulation of proliferation and EMT under oxygen deprivation in hypoxia-sensitive HepG2 cells. 
To investigate the oxygen concentration-dependent changes, HepG2 cells were cultured for 24 h under 0%, 1%, 
3%, and 21% oxygen concentration. The expression of HIF1α was upregulated under hypoxia (3% and below) 
(Fig. 3A). The expression of PCNA, an indicator of proliferation, was reduced at 1% and 0% oxygen. Unlike 
PCNA, the glycolysis-related proteins, HK2 and GLUT1, showed continuously increased expression according to 
the oxygen concentration (Fig. 3A). Furthermore, the expression of the regulatory transcriptional factors of EMT, 
Snail/Slug and N-cadherin, was determined. Under severe hypoxic condition (below 1% oxygen), Snail/Slug was 
upregulated. The expression of N-cadherin was increased under mild hypoxia (3% and 1% oxygen). Thus, we 
determined the effect of hypoxia on glucose metabolism and proliferation-related protein in vitro.
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Hypoxia versus Ki67, GLUT1, and EMT expression in HepG2-xenograft model. In the HepG2- 
xenograft model, the expression of GLUT1 (b), the distribution of pimonidazole staining (c, as a hypoxia marker), 
and the expression of Ki67 (f) were assessed in various tumor regions to determine the effect of hypoxia on 
glucose metabolism and cellular proliferation (Fig. 3B). Hypoxic regions with positive pimonidazole staining 
showed decreased Ki67 expression compared with that in non-hypoxia region with negative pimonidazole 
staining. These results were consistent with those obtained for areas with hypoxia (≤3% oxygen) and decreased 
cellular proliferation. In HepG2-xenograft model, we observed the upregulation of GLUT1 expression in the 
pimonidazole-positive hypoxic regions, and it was continuously expressed in some of the necrotic areas, regard-
less of pimonidazole staining (Fig. 4A). Rapidly growing tumors suffer from oxygen deprivation for an extended 
period due to insufficient blood supply, resulting in necrotic tumor cell death in the core region of tumors. 
Therefore, we cultured HepG2 cells under oxygen-free environment for 3 days under 0% oxygen. The expression 
of HIF1α was increased after one day under oxygen deprivation. However, following increased incubation time 
with 0% oxygen, the expression of HIF1α was reduced and that of GLUT1 was increased. Thus, even if our exper-
imental conditions could not mimic the necrotic region, we assumed that a 3-day incubation with 0% oxygen 
could mimic the necrotic region. Thus, our result indicates that GLUT1 expression was positive in the necrotic 
region because the few cells that survived under oxygen deprivation for an extended period still maintained 
Figure 1. Differences in the expression of HIF1α, GLUT1, CD31, and EMT-related proteins in HCC samples 
based on 18F-FDG uptake. (A,B) Expression of HIF1α, GLUT1, and CD31 in human HCC with (A) low 
18F-FDG uptake or (B) high 18F-FDG uptake. Immunostaining with antibodies against indicated proteins 
performed on FFPE tissues. Nuclei were counterstained with DAPI. (C) Immunofluorescence detection using 
antibodies against GLUT1, vimentin, and Ki67 in FFPE tissues from human patients with HCC. Nuclei were 
counterstained with DAPI. Scale bars: 100 μm.
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GLUT1 expression (Fig. 4B,C). We also measured the uptake of radiolabelled glucose in HepG2 cells by in vitro 
binding assays to determine whether GLUT1 still functions in the necrotic area. The uptake of radioactive glucose 
persisted for 3 days, even under oxygen deprivation (Fig. 4D). Thus, GLUT1 expression may not be a sufficient 
marker of inducing EMT process.
Synergistic expression of EMT-related proteins under hypoxia and glucose deprivation. In 
the core of tumors, there might be extreme metabolic stress resulting from oxygen and glucose depletion. 
Unlike the hypoxia region stained by pimonidazole, the actual availability of glucose in the diffusion restricted 
regions showing increased GLUT1 expression could not be measured in the xenograft. Therefore, the syner-
gistic effect of glucose and oxygen deprivation under hypoxia on the expression of EMT-related proteins was 
assessed in vitro. As expected, cell proliferation was reduced after glucose deprivation under 1% hypoxic condi-
tion (Supplementary Fig. S5). However, as shown in Fig. 5A, severe glucose deprivation at 1% oxygen concen-
tration increased the expression of N-cadherin and Snail/Slug, suggesting that glucose deprivation and hypoxia 
synergistically increased EMT-related proteins. Indeed, glucose deficiency-mediated dysregulated expres-
sion of EMT-related proteins was less than that in the hypoxic state under normoxic conditions. Interestingly, 
although the expression of EMT-related proteins was upregulated, HiF1α expression was abolished in HepG2 
cells grown in a glucose-deprived medium under hypoxia (Fig. 5A). We observed similar results using Hep3B 
cells (Supplementary Fig. S6A). To further validate our findings, Hif1α was overexpressed in HepG2 cells and 
Hep3B cells exposed to different concentrations of glucose (0, 0.1 and 25 mM) under hypoxia. The increased 
Hif1α expression also reduced after incubation of cells in a low or no glucose medium under hypoxia (Fig. 5B and 
Supplementary Fig. S6B). The expression of EMT-related proteins was downregulated with the increase in the 
concentration of glucose in both MOCK- and HIF1α-transfected HepG2 cells. HepG2 cells (Fig. 5C and D) and 
Hep3B cells (Supplementary Fig. S6C,D) incubated with 0.1 mM glucose under hypoxia exhibited a higher inva-
sion potential than did those incubated with 25 mM glucose. Usually, it is difficult to identify EMT-positive tumor 
cells in a hypoxia-negative region in vivo and in patients with HCC. Thus, we treated HepG2 cells with glucose 
deprivation medium under hypoxia with glutamine, another major nutrient in cancer metabolism. The glucose 
deprivation-induced reduction of Hif1α recovered after treatment with glutamine (Supplementary Fig. S7A). 
Moreover, the expression of Hif1α in the glutamine transporter ASCT2-positive region was much more than that 
in the ASCT2-negative region in the HepG2-xenograft model (Supplementary Fig. S7B). Taken together, these 
results suggest that increased EMT was associated with glucose deprivation under hypoxia in HCC cells.
Synergistic expression of EMT-related proteins under hypoxia and proliferation. In our study, 
we mimicked the microenvironment that induces the EMT process. In Fig. 5, we showed that, under hypoxic con-
ditions, glucose-deprived HCC cells upregulated the expression of N-cadherin and snail/slug and downregulated 
E-cadherin. Interestingly, HCC cells with 0 mM and 0.1 mM glucose showed a decrease in PCNA as compared to 
HCC cells with high glucose (Fig. 5A). Thus, our hypothesis is that the induction of EMT-related proteins partly 
depends on the proliferation rate of HCC cells. Proliferating cell nuclear antigen (PCNA) is known as a molec-
ular marker for proliferation35. Thus, PCNA expression was knocked down in HepG2 HCC cells, which were 
then incubated with various glucose concentrations under hypoxic conditions. Knockdown of PCNA in HepG2 
and Hep3B cells significantly increased the expression of N-cadherin and Snail/Slug in the complete absence of 
glucose under hypoxia (Fig. 6A and Supplementary Fig. S8A). However, the addition of glucose to the medium 
reduced the induction of EMT-related proteins in PCNA-KD HCC cells. These results showed that the prolifera-
tion of HCC cells also plays an important role in induction of EMT process.
Figure 2. Response of HCC tumor cells to hypoxia. (A) Expression of HIF1α under hypoxic conditions. 
Three HCC cell lines (HepG2, Hep3B, and Huh7) were exposed to hypoxic conditions (1% oxygen). After the 
indicated incubation period, HIF1α and β-actin expression levels were evaluated by western blotting. Data 
shown represents one of three independent experiments with similar results.
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Next, we determined whether the expression of EMT-related proteins in hypoxic regions changes depend-
ing on the oxygen concentration in vivo. Necrotic regions are commonly found in the core region in response 
to extreme metabolic stress resulting from oxygen and glucose depletion. Because we could not measure glu-
cose deprivation directly in the tumor tissue, we examined the co-expression of EMT-proteins with Ki67 next 
to the necrotic region. As shown in Fig. 6B, the expression of Ki67 varied depending on the distance from the 
necrotic region. Similar to the in vitro experiments, we observed a negative correlation between Ki67 and expres-
sion of N-cadherin or vimentin. Thus, glucose deprivation under a hypoxic condition effectively dysregulates 
EMT-related proteins in vivo. Thus, our data reveal a unique microenvironment comprising glucose deprivation, 
hypoxia, and low proliferation rate for inducing EMT process under hypoxia.
Discussion
The main aim of the current study was to investigate the microenvironment factors that are favorable for metas-
tasis in HCC. Previous studies suggested that high expression of HIF1α and GLUT1 in HCC is a major causative 
factor for metastasis36,37. However, our current data suggest that the EMT process is very complex and is caused 
by a combination of hypoxia, low cell proliferation, and poor glucose diffusion.
Previous studies suggested that high expression of HIF1α38–40 and GLUT141,42 in HCC are major causative 
factors for metastasis. The rapid growth rate of cancer cells induces blood vessel leakage, chaotic structure, and 
non-laminar blood flow. The blood vessels formed in the tumor do not undergo normal physiological angiogen-
esis, and the nutritional supply to the tumor is abnormal. Accordingly, the core of the tumor might have extreme 
metabolic stress such as not only oxygen but also nutrient depletion. Therefore, hypoxia itself may not be suf-
ficient to mimic the microenvironment of the tumor. In this study, the synergistic effect of glucose and oxygen 
deprivation under hypoxia on the expression of EMT-related proteins was assessed in vitro. We found that severe 
glucose deprivation in addition to hypoxia played an additive role in increasing the expression of N-cadherin as 
Figure 3. Expression of hypoxia-related proteins in HepG2 cells. (A) HepG2 cells were exposed to the 
indicated hypoxic conditions. After 24 h, HIF1α, GLUT1, HK2, PCNA, N-cadherin, E-cadherin, Snail/
Slug, and β-actin expression levels were evaluated by western blotting. Data shown represents one of three 
independent experiments with similar results. (B) Immunofluorescent staining with antibodies against (b, g) 
GLUT1, (c) pimonidazole, and (f) Ki67 performed on FFPE tissues from HepG2-xenograft model. Nuclei were 
counterstained with DAPI. In parallel, immunohistochemistry was performed using HIF1α antibodies. Scale 
bars: 100 μm.
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well as Snail/Slug. It seems that glucose deprivation and hypoxia acted synergistically to increase EMT-related 
proteins. In addition, our study demonstrated a reduction in endo- and exogenous HIF1a expression by glucose 
deprivation under hypoxia. Similar to our study, the study conducted by Kwon et al., showed that glucose depriva-
tion affected the reduced accumulation of HIF-1α under hypoxic conditions by disrupting translational processes 
in prostatic cancer cells43. In addition, Hubbi et al., also showed that chaperone-mediated autophagy promotes 
HIF-1α degradation after HCC cells are exposed to low glucose culture medium under hypoxic conditions44. 
Clinical metastasis prediction in tumor patients often fails when using a single parameter. For instance, Hoskin et 
al., failed to predict local control or metastasis-free survival by hypoxia markers in bladder cancer45.
To investigate the oxygen concentration-dependent changes in cellular proliferation and EMT, HepG2 
cells were grown under different concentrations of oxygen (0%, 1%, 3%, and 21%) in our study. While HIF1α 
and GLUT1 were upregulated at less than 3% oxygen, the expression of PCNA, as a marker of proliferation, 
increased at 3% oxygen and started to reduce at 0% and 1% oxygen. EMT-related proteins began to be upregu-
lated from below 3%. This suggested that cellular proliferation could be decreased in spite of increased GLUT1 
expression. Using pimonidazole as a hypoxic marker, the xenograft model using HepG2 cells demonstrated 
that pimonidazole-stained hypoxic tumor regions showing high GLUT1 but low Ki67 expression had high 
EMT expression. Therefore, the hypoxia-induced decreased cellular proliferation was correlated with increased 
Figure 4. GLUT1 expression in the necrotic region. (A) Expression of pimonidazole and GLUT1 in hypoxia 
and necrotic region of HepG2-xenograft model. Immunostaining with antibodies against indicated proteins 
performed on FFPE tissues from HepG2-xenograft model. Nuclei were counterstained with DAPI. (B) 
HepG2 cells were plated on coverslips in 24-well plates and incubated under severe hypoxic condition (0%). 
After indicated incubation times, the cells were fixed and immune-stained for GLUT1 protein. (C) HIF1α, 
GLUT1, and actin expression levels were measured using western blotting. Data shown represents one of 
three independent experiments with similar results. (D) In samples parallel to “C,” the uptake of 18F-FDG was 
measured using a gamma-counter (right panel). The data were analyzed independently using three replicates 
each (n = 3). Data are presented as means ± standard deviations.
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EMT-related protein expression. Gastric cancer patients with regional lymph node metastasis, distant metastasis, 
or lymphatic invasion were found to have significantly lower proliferation46. Moreover, upregulation of Twist1, an 
EMT activator, has been found to be associated with reduced skin cancer cell proliferation in vivo47. The reduction 
in cancer cell proliferation associated with the activation process of EMT is generally associated with increased 
resistance to chemotherapy that targets highly proliferating cells24,48.
There has been an emerging interest in the effects of metabolic processes on metastasis. The increased expres-
sion of GLUT1 upon exposure to hypoxia leads to a stimulation of glucose transport49–51. However, our in vitro 
and animal experiments showed that GLUT1 was consistently expressed in necrotic areas where glucose is no 
longer required for the production of cellular energy. A weak correlation was observed between hypoxic volume 
Figure 5. Increased EMT-related protein expression after glucose-deprivation under hypoxia. (A) HepG2 cells 
were incubated with various concentrations of glucose under normoxia or hypoxia (1% oxygen). After 8 h, 
HIF1α, GLUT1, HK2, N-cadherin, E-cadherin, Snail/Slug, PCNA, and β-actin expression levels were examined 
by western blotting. The images have been cropped from those of different blots exposed for the same time. Data 
shown represents one of three independent experiments with similar results. (B) HepG2 cells were transfected 
with MOCK or pCMV3- HIF1α. After 24 h, HepG2 cells were incubated with the indicated concentration of 
glucose under hypoxia (1% oxygen) for 8 h. HIF1α, N-cadherin, E-cadherin, Snail/Slug, and β-actin expression 
levels were then examined by western blotting. The images have been cropped from those of different blots 
exposed for the same time. Data shown represents one of three independent experiments with similar results. 
(C) HepG2 cells were incubated with the indicated concentration of glucose under hypoxia (1% oxygen) for 8 
h. HepG2 cells penetrating the membrane were fixed and visualized by crystal violet staining. (D) Quantitative 
analyses were performed for the cells migrating through the Matrigel-coated filter. Five random fields of each 
test at ×200 magnification were counted (±standard deviation) in 3 independent experiments. *p < 0.05.
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and hypermetabolic volume in non-small cell lung cancer patients52. Moreover, GLUT1 was expressed in tumor 
regions where EMT-related proteins were not increased. Thus, GLUT1 expression was necessary but not suffi-
cient for induction of EMT process. Indeed, patients with HCCs with increased 18F-FDG uptake were correlated 
with increased GLUT1 expression. However, in line with the in vitro/in vivo data, HCCs with low Ki67 in spite 
of increased GLUT1 expression were correlated with increased EMT-related proteins, such as N-cadherin. These 
results might have an important implication in the use of 18F-FDG-PET/CT as a useful diagnostic tool for eval-
uating metastasis49,53,54. A previous study by our group found that increased 18F-FDG uptake in patients with 
HCC was associated with an increased frequency of metastasis33. However, only 10 out of 34 patients (29.4%) 
with increased 18F-FDG uptake in the primary tumor presented metastasis, while 69.6% did not. These results 
could be attributable to 18F-FDG uptake being indicative of the expression of GLUT1 but not cell proliferation 
and hypoxia. Recently, Zhang et al. reported that it is unknown whether 18F-FDG can be used to monitor liver 
metastasis of colorectal cancer55. Thus, to enhance the prediction of metastasis, parameters such as glucose and 
cell proliferation, have to be considered based on our results. Radiopharmaceuticals have investigated tumor 
biology. 18F-FMISO, which selectively binds to hypoxic cells in human tumors, has been used for staging and 
follow-up of multiple malignant tumors including glioblastoma, lung cancer, head and neck cancer, and breast 
cancer56–59. Currently, few tracers such as 18F-FLT measure proliferation. Saga et al. assessed the clinical potential 
of FLT-PET/CT imaging to detect cell proliferation in response to radiotherapy in patients with non-small cell 
lung carcinoma60. As we have proved above, one parameter cannot predict metastasis. Thus, based on our in vitro 
and in vivo experiments, we propose that combining 18F-FLT and FMISO with 18F-FDG PET can possibly pro-
vide an improved diagnostic and prognostic tool for metastasis and response to anti-cancer agents.
HCC is a heterogeneous disease, from both a clinical and a molecular viewpoint. In this study, we performed 
in vitro and in vivo analysis to determine the microenvironments that induce EMT process in hypoxic areas of 
liver cancer tissues. Contrary to other studies that attempted to link EMT process to only one condition, for 
example, oxygen concentration, the current study investigated integrated conditions that induce EMT process. 
Overall, our data revealed that HCC cells begin to induce EMT process or cell invasion when they encounter a 
Figure 6. Increased EMT-related protein expression in low proliferative cells under hypoxia. (A) HepG2 cells 
were transfected with scrambled siRNA oligos or siRNA oligos against PCNA. After 24 h, HepG2 cells were 
incubated with various concentrations of glucose under hypoxic (1% oxygen) condition for 8 h. PCNA, HIF1α, 
N-cadherin, Snail/Slug, and β-actin expression levels were then examined by western blotting. Data shown 
represents one of three independent experiments with similar results. (B) Immunofluorescent staining with 
indicated antibodies performed on FFPE tissues from HepG2-xenograft model. Nuclei were counterstained 
with DAPI. Scale bars: 100 μm. N.A; necrotic area.
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combination of hypoxia, glucose deficiency, and reduced proliferation signals. These findings could be very useful 
in clinical practice during PET analysis for predicting the prognosis of metastasis and therapy outcome.
Methods
Human HCC samples. This study was approved by the Institutional Review Board at Yonsei University 
Health System Severance Hospital (Seoul, South Korea). All the experiments were performed following relevant 
guidelines and regulations (Yonsei IRB number: 4-2015-0904). Prior informed consents were obtained from all 
patients. We selected 23 curative surgical resection-treated patients in whom 18F-FDG PET/CT was performed 
for preoperative staging at our institution. The 18F-FDG uptake for the quantitative evaluation of HCC was per-
formed as previously reported33. Among the 23 selected patients, 13 showed low 18F-FDG uptake (TLR, ≤1.62) 
and 10 showed high 18F-FDG uptake (TLR, >1.62).
Cell culture and treatment. All cell lines were purchased from the Korean Cell Line Bank (Seoul, South 
Korea). HepG2 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 supplemented with 10% 
(v/v) foetal bovine serum (FBS) and 100 U penicillin/100 µg-streptomycin at 37 °C and 5% CO2 atmosphere. 
Hep3B and Huh7 cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% (v/v) FBS 
and 100 U penicillin/100 µg streptomycin at 37 °C and 5% CO2 atmosphere. All cells were routinely tested for 
mycoplasma and found to be contamination-free. Moreover, they were maintained in culture for a maximum of 5 
passages after thawing. Hypoxia was achieved by incubating the cells in an incubator (STEMCELL Technologies 
Inc.) in which the oxygen was replaced by pure nitrogen. The gas proportions used were 21% O2: 21% O2 and 5% 
CO2; 3% O2: 3% O2, 5% CO2, and 92% N2; 1% O2: 1% O2, 5% CO2, and 94% N2 and 0% O2: 0% O2, 5% CO2, and 
95% N2. Cells were cultured for indicated incubation time and were harvested for further analysis. The prolifer-
ation of HepG2 cells was estimated using a cell counting kit (CCK-8) from Dojindo Laboratories (Kumamoto, 
Japan). The HepG2 cells were cultured with various concentrations of glucose. After 24 h of incubation, HepG2 
cells were incubated under hypoxic (1% oxygen) condition for additional 8 h. The absorbance was measured at 
a wavelength of 450 nm using a microplate reader (Molecular Devices, California, US). For small interfering 
RNA (siRNA)-mediated knockdown of PCNA, HepG2 cells were transfected with scrambled siRNA and siP-
CNA (Bioneer, Daejeon, Korea) using Lipofectamine following the manufacturer’s instruction. The sequences 
of siRNA targeting human PCNA are as follows: (i) sense: 5′- CAGCAUAUACUGAAGUCUUtt-3′; antisense: 
5′- AAGACUUCAHUAUAUGCUGtt-3′.
Invasion assay. The cell invasion assays were performed as described previously33. Invasion assays were per-
formed using Corning® BioCoat™ Matrigel® Invasion Chamber (BioCoat; BD Biosciences, Heidelberg, Germany). 
A total of 100,000 cells in medium containing 0.1 mM or 25 mM glucose were added into the upper chamber of 
the insert with 8-mm pores in 24-well tissue culture plates. The lower well was filled with a medium supple-
mented with 25 mM glucose, and after 8 h, the invaded cells were fixed for 10 min (4% v/v formaldehyde in PBS) 
before staining with 0.1% crystal violet for 15 min, followed by washing with PBS. Images were acquired using an 
Olympus BX53 microscope with Olympus Cell Sens software (Carl Zeiss Microscopy, GmbH, Jena, Germany).
Animal preparation. All animal procedures were performed in accordance with the guidelines of the 
Animal Care Committee at the Yonsei University Health System Institutional Animal Care and were approved 
by the Animal Care Committee at the Yonsei University Health System Institutional Animal Care prior to exper-
iments (IACUC number 2015‐0195). Male BALB/c-nu mice of SPF grade, 4‒5-weeks old, were purchased from 
Central lab. Animal inc (Korea). HCC cells growing exponentially in vitro were trypsinised and harvested for 
tumor implantation. All animal manipulations were performed under sterile conditions. HCC cells (at a concen-
tration of 100,000 cells/ml) at the logarithmic growth phase were washed twice with serum-free culture solution 
and suspended in Matrigel (BD Biosciences). The cells (0.1 ml) were inoculated subcutaneously on the back of 
each nude mouse. The animals were provided with sterilized food and water. The mice were weighed, and the 
tumor growth in nude mice was monitored carefully once a week. After 6 weeks, mice were injected intravenously 
(tail vein) with 60 mg/kg of pimonidazole solution (Hypoxyprobe™, Hypoxyprobe, Inc.). After 90 min, mice were 
sacrificed under anesthesia and dissected. Tumor tissues were collected and fixed using 4% paraformaldehyde for 
pathology study.
Immunostaining. Immunohistochemistry (IHC) and immunofluorescence (IF) were performed as 
described previously61 using various antibodies (Supplementary Fig. S1). For immunocytochemistry (ICC), 
HepG2 cells were seeded on glass-bottomed cell culture dishes (NEST Biotechnology, Jiangsu, China) and incu-
bated for 24 h under hypoxic conditions. Then, cells were fixed in 4% paraformaldehyde for 30 min and washed 
three times with PBS. Next, the cells were incubated in PBS containing 0.25% Triton X-100 for 10 min and 
blocked with blocking solution (3% bovine serum albumin, 0.25% Triton X-100 in PBS). Cells were treated for 
30 min followed by incubation overnight at 4 °C with a diluted primary antibody against GLUT1 in blocking 
solution. The next day, the cells were washed three times with PBS and incubated with diluted secondary antibody 
(1:200, Invitrogen, Oregon, USA) in blocking solution for 1 h. After washing the cells in PBS, Hoechst 33258 
was used to stain the nuclei. Images were acquired using an Olympus BX53 microscope with Olympus Cell Sens 
software (Carl Zeiss Microscopy, GmbH, Jena, Germany). Quantification of fluorescence in microscopic images 
stained with GFP (Green) and DsRed (Red) was carried out using IMT i-Solution software (Martin Microscope 
Company, Easley, USA).
In vitro 18F-FDG uptake assay. HepG2 cells were plated into 6-well plates (150,000 cells/well). The fol-
lowing day, cells were incubated under hypoxic conditions. After 0, 1, 2, and 3 days, the culture medium was 
exchanged with glucose-free DMEM (Thermo Fisher Scientific). Approximately, 0.0037 MBq of 18F-FDG was 
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added to the cells, which were then incubated for 20 min. The cells were then washed three times with PBS, after 
which sodium dodecyl sulfate (SDS) lysis buffer (60 mM Tris-HCl, pH 6.8, 1% SDS) was added to each well. 
The cell lysates were collected, and the amount of radioactivity incorporated into the cells was measured using a 
gamma counter (Perkin Elmer, Waltham, MA, USA). The measured radioactivity was normalized to the protein 
content in the cell lysates, which was calculated using the Nanodrop ND-1000 spectrophotometer (Denovix, 
Wilmington, USA).
Protein extraction and western blotting. Total proteins were extracted from cells, and western blotting 
was performed as previously reported33. The primary antibodies used were: PCNA (Cell Signaling Technology, 
Danvers MA, USA; #13110; dilution 1:5000); Hexokinase II (EPR20839; 1:500), HIF1α(1:1000), GLUT1 (1:2000), 
N cadherin (5D5; 1:1000), and Snail/Slug (1:1000), all procured from Abcam (Cambridge, UK); and β-actin-HRP 
(Santa Cruz Biotechnology, Dalla TX, USA; C4; dilution 1:1000). Western blotting experiments from biological 
replicates showed similar expression data, attesting to the reproducibility of the results. For band quantification, 
images were analyzed using Image Lab software (Bio-Rad, Hercules, California, USA). For band quantification, 
images were analyzed using IMT i-Solution software Martin Microscope Company, Easley, USA).
Real-time PCR. Total RNA was extracted with TRIzol (Invitrogen). cDNAs were synthesized from 500 ng 
of total RNA using the ReverTra Ace® qPCR RT Master Mix with gDNA Remover (TOYOBO, Osaka, Japan). 
Quantitative RT-PCR was conducted on C1000™ Thermal Cycler (Bio-Rad) using SYBR® Green Realtime PCR 
Master Mix (TOYOBO, Japan). The gene expression levels were normalized by beta-2 microglobulin (B2M) mRNA 
expression levels of corresponding cDNA samples. All PCR primers were purchased from Bioneer (Daejeon, 
Korea). The following primers were used: HIF1 (Forward 5′-CTGACCCTGCACTCAATCAAG-3′, Reverse 
5′-TGGGACTATTAGGCTCAGGTG-3′), CDH2 (Forward 5′-GAGACTTGCGAAACTCCAGAC-3′, Reverse 
5′-CATTAAGCCGAGTGATGGTCC-3′), PCNA (Forward 5′-TGTGCAAAAGACGGAGTGAAA-3′, Reverse 5′-AGT 
TCAGGTACCTCAGTGCAA-3′), SNAl1 (Forward 5′-CCCCAATCGGAAGCCTAACTA-3′, Reverse 5′-ACAGAG 
TCCCAGATGAGCATT -3′), B2M (Forward 5′-TTACTCACGTCATCCAGCAGA-3′, Reverse 5′-AGAAAGACCA 
GTCCTTGCTGA-3′).
TCGA data analysis. mRNA levels were obtained from the Cancer Genome Atlas (TCGA) Liver hepato-
cellular carcinoma dataset available at the OncoLnc (www.oncolnc.org) TCGA data portal. A set of 360 HCC 
samples with high and low gene expression groups (50-50 percentile) was used for constructing graphs showing 
correlations between different genes. GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA) was used for 
mapping.
Statistical analysis. Statistical analyses were performed using GraphPad Prism Software (GraphPad 
Software, Inc., San Diego, CA). Results are expressed as mean ± SE (range). P values <0.05 were considered 
statistically significant. Comparisons between groups were made using the Mann-Whitney test.
Data availability
The datasets generated and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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